The Myelin Associated Glycoprotein (MAG) SGPG IgM Antibody Test detects antibodies against MAG and sulfated glucuronyl paragloboside (SGPG), markers linked to demyelinating neuropathies. Elevated IgM antibodies may indicate autoimmune neurological disorders, including peripheral neuropathy or chronic inflammatory demyelinating polyneuropathy. This test supports diagnosis, monitoring, and evaluation of immune-mediated nerve damage.

The MAG IgM Antibody Test supports assessment of immune-mediated peripheral neuropathies by quantifying antibodies to myelin-associated glycoprotein. Positive results are often seen in distal acquired demyelinating symmetric neuropathy and in IgM paraproteinemias. This test helps clinicians clarify etiology when nerve conduction studies show demyelination, refine prognosis, and monitor response to therapy alongside SPEP/IFE and other autoimmune neuropathy markers.

 The Antidepressants Panel 1 test is a laboratory assay designed to detect and measure the concentration of specific antidepressant medications in a patient's serum or plasma. This helps in assessing medication adherence, verifying therapeutic levels, or detecting potential drug interactions.